Ascorbyl Palmitate

Ascorbyl Palmitate

SCHEMBL19741752

CCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC(=O)C(O)=C1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 1.00
HSPD1 P10809 1/20 1.00
HSPE1 P61604 1/20 1.00
TST Q16762 1/20 1.00
RECQL P46063 1/20 1.00
BLM P54132 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
LMNA P02545 3/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
PPM1A P35813 2/20 0.49
KDM4E B2RXH2 1/20 0.48
DUSP3 P51452 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ENPP2 Q13822 4/20 0.46
LPAR6 P43657 1/20 0.46
LPAR1 Q92633 1/20 0.46
LPAR4 Q99677 1/20 0.46
LPAR5 Q9H1C0 1/20 0.46
LPAR2 Q9HBW0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8470179 1.00 MAPT (1.00) MAPTHSPD1HSPE1TSTRECQL
SCHEMBL22749131 1.00 MAPT (1.00) MAPTHSPD1HSPE1TSTRECQL
Ascorbyl Palmitate SCHEMBL14429918 1.00 MAPT (1.00) MAPTHSPD1HSPE1TSTRECQL
SCHEMBL22749146 1.00 MAPT (1.00) MAPTHSPD1HSPE1TSTRECQL
SCHEMBL22749133 1.00 MAPT (1.00) MAPTHSPD1HSPE1TSTRECQL
SCHEMBL8472638 1.00 MAPT (1.00) MAPTHSPD1HSPE1TSTRECQL
Ascorbyl Palmitate SCHEMBL11170086 1.00 MAPT (1.00) MAPTHSPD1HSPE1TSTRECQL
Ascorbyl Stearate SCHEMBL4574542 1.00 MAPT (1.00) MAPTHSPD1HSPE1TSTRECQL
SCHEMBL1762372 1.00 MAPT (1.00) MAPTHSPD1HSPE1TSTRECQL
SCHEMBL1762325 1.00 MAPT (1.00) MAPTHSPD1HSPE1TSTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3928619-A1 A METHOD FOR TREATING AND CONTROLLING POST-HARVEST PHYSIOLOGICAL DISORDERS IN FRUIT VIA EDIBLE COATINGS Decco Worldwide Post-Harvest Holdings B.V. (NL) 2021-12-29 EP claimed
US-20250143331-A1 METHOD FOR TREATING AND CONTROLLING POST-HARVEST PHYSIOLOGICAL DISORDERS IN FRUIT VIA EDIBLE COATINGS DECCO WORLDWIDE POST-HARVEST HOLDINGS B.V. (NL) 2025-05-08 US disclosed
US-20230200404-A1 METHOD FOR TREATING AND CONTROLLING POST-HARVEST PHYSIOLOGICAL DISORDERS IN FRUIT VIA EDIBLE COATINGS DECCO WORLDWIDE POST-HARVEST HOLDINGS B.V. (NL) 2023-06-29 US disclosed
US-20220259500-A1 AGENT FOR PREVENTION OF DECOMPOSITION OF BIOPYRRIN RESVO INC. (JP) 2022-08-18 US disclosed
EP-3998325-A1 AGENT FOR PREVENTION OF DECOMPOSITION OF BIOPYRRIN Resvo Inc. (JP) 2022-05-18 EP disclosed
EP-3928619-A1 A METHOD FOR TREATING AND CONTROLLING POST-HARVEST PHYSIOLOGICAL DISORDERS IN FRUIT VIA EDIBLE COATINGS Decco Worldwide Post-Harvest Holdings B.V. (NL) 2021-12-29 EP disclosed
EP-3684177-A1 A METHOD FOR TREATING AND CONTROLLING POST-HARVEST PHYSIOLOGICAL DISORDERS IN FRUIT VIA EDIBLE COATINGS Decco Worldwide Post-Harvest Holdings B.V. (NL) 2020-07-29 EP disclosed
US-20200214305-A1 A METHOD FOR TREATING AND CONTROLLING POST-HARVEST PHYSIOLOGICAL DISORDERS IN FRUIT VIA EDIBLE COATINGS DECCO WORLDWIDE POST-HARVEST HOLDINGS B.V. (NL) 2020-07-09 US disclosed
EP-2928841-B1 ANTI-SAGGING GYPSUM PRODUCT AND A METHOD TO MANUFACTURE SAINT GOBAIN PLACO (FR) 2019-11-13 EP disclosed
US-10273408-B2 Wavelength conversion member, backlight unit including wavelength conversion member, and liquid crystal display device FUJIFILM CORPORATION (JP) 2019-04-30 US disclosed
WO-2019058211-A1 A METHOD FOR TREATING AND CONTROLLING POST-HARVEST PHYSIOLOGICAL DISORDERS IN FRUIT VIA EDIBLE COATINGS DECCO WORLDWIDE POST-HARVEST HOLDINGS B.V. (NL) 2019-03-28 WO disclosed
US-20180072949-A1 WAVELENGTH CONVERSION MEMBER, BACKLIGHT UNIT INCLUDING WAVELENGTH CONVERSION MEMBER, AND LIQUID CRYSTAL DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2018-03-15 US disclosed
US-20180072949-A1 WAVELENGTH CONVERSION MEMBER, BACKLIGHT UNIT INCLUDING WAVELENGTH CONVERSION MEMBER, AND LIQUID CRYSTAL DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2018-03-15 US disclosed
US-20170368052-A1 CRYSTAL FORMS OF APOMORPHINE AND USES THEREOF NEURODERM, LTD. (IL) 2017-12-28 US disclosed
CN-104345098-B A kind of method measuring antioxidant content in tablet of tibolone CHINA RESOURCES ZIZHU PHARMACEUTICAL CO., LTD. (CN) 2016-04-13 CN disclosed
CN-104345098-A Method for determining antioxidant content in tibolone tablets CHINA RESOURCES ZIZHU PHARMACEUTICAL CO LTD 2015-02-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170368052-A1 CRYSTAL FORMS OF APOMORPHINE AND USES THEREOF PARK7, SNCA, SLC6A3 MAPT 22/4885HSPD1 1143/4885HSPE1 1685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.